Netarsudil mesylate/Latanoprost

N/A

Report date: 2025/03/12 15:25:51

Base Information

Drug NameNetarsudil mesylate/Latanoprost
Drug Alias Name拉坦前列素/Netarsudil MesylateLatanoprost and Netarsudil Mesylate拉坦前列素/奈他地尔Netarsudil Mesylate and LatanoprostNetarsudil/latanoprost +[11] 
ClassificationSmall molecules
Mechanisms of ActionProstanoid FP receptor agonistsRho-associated kinases inhibitorsNorepinephrine transporter inhibitors
TargetsProstanoid FP receptorRho-associated kinasesNorepinephrine transporter
Therapy Area/IndicationsGlaucoma, Open-AngleOcular Hypertension
Global Approved IndicationsGlaucoma, Open-AngleOcular Hypertension
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/03/12
Country/TerritoryCzechiaBelgiumUnited States +[13] 
CombinationsYes LatanoprostNetarsudil Dimesylate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAerie Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSanten OyAlcon Laboratories Inc
Inactive CompaniesAlconAerie Pharmaceuticals Inc
Active IndicationsGlaucoma, Open-AngleOcular Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeS01E
Related LinksN/A